Compare TXG & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TXG | RDI |
|---|---|---|
| Founded | 2012 | 1937 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Movies/Entertainment |
| Sector | Industrials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 23.6M |
| IPO Year | 2019 | N/A |
| Metric | TXG | RDI |
|---|---|---|
| Price | $17.99 | $1.07 |
| Analyst Decision | Hold | |
| Analyst Count | 14 | 0 |
| Target Price | ★ $16.18 | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 36.0K |
| Earning Date | 02-12-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $642,823,000.00 | $211,292,000.00 |
| Revenue This Year | $5.15 | N/A |
| Revenue Next Year | N/A | $13.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 5.25 | ★ 7.11 |
| 52 Week Low | $6.78 | $1.00 |
| 52 Week High | $23.56 | $1.65 |
| Indicator | TXG | RDI |
|---|---|---|
| Relative Strength Index (RSI) | 52.14 | 47.38 |
| Support Level | $17.26 | $1.01 |
| Resistance Level | $19.43 | $1.10 |
| Average True Range (ATR) | 1.17 | 0.04 |
| MACD | -0.28 | 0.00 |
| Stochastic Oscillator | 50.08 | 42.86 |
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.